BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28167670)

  • 1. Salmonella enterica Serovar Typhi Lipopolysaccharide O-Antigen Modification Impact on Serum Resistance and Antibody Recognition.
    Kintz E; Heiss C; Black I; Donohue N; Brown N; Davies MR; Azadi P; Baker S; Kaye PM; van der Woude M
    Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28167670
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
    Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
    PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by Salmonella enterica serovar Typhi.
    Crawford RW; Wangdi T; Spees AM; Xavier MN; Tsolis RM; Bäumler AJ
    mBio; 2013 Jul; 4(4):. PubMed ID: 23860765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Horizontally acquired glycosyltransferase operons drive salmonellae lipopolysaccharide diversity.
    Davies MR; Broadbent SE; Harris SR; Thomson NR; van der Woude MW
    PLoS Genet; 2013 Jun; 9(6):e1003568. PubMed ID: 23818865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salmonella enterica serovar Typhi O:1,9,12 polysaccharide-protein conjugate as a diagnostic tool for typhoid fever.
    Zuñiga J; Lillo L; Shin JJ; Machavarapu RL; Quiroga T; Goycoolea M; Matsuhiro B; Aron-Hott L; Godfrey HP; Cabello FC
    J Clin Microbiol; 2005 Sep; 43(9):4545-50. PubMed ID: 16145105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
    Ali A; An SJ; Cui C; Haque A; Carbis R
    Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Vi Negative Isolates of Salmonella Enterica Serovar Typhi.
    Haque A
    Adv Exp Med Biol; 2018; 1052():9-18. PubMed ID: 29785477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.
    Wahid R; Zafar SJ; McArthur MA; Pasetti MF; Levine MM; Sztein MB
    Clin Vaccine Immunol; 2014 Mar; 21(3):427-34. PubMed ID: 24429069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
    Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A; Pakkanen SH; Siitonen A; Karttunen R; Kantele JM
    Vaccine; 2012 Nov; 30(50):7238-45. PubMed ID: 23084770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi.
    Harris JB; Baresch-Bernal A; Rollins SM; Alam A; LaRocque RC; Bikowski M; Peppercorn AF; Handfield M; Hillman JD; Qadri F; Calderwood SB; Hohmann E; Breiman RF; Brooks WA; Ryan ET
    Infect Immun; 2006 Sep; 74(9):5161-8. PubMed ID: 16926408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase variation controls expression of Salmonella lipopolysaccharide modification genes by a DNA methylation-dependent mechanism.
    Broadbent SE; Davies MR; van der Woude MW
    Mol Microbiol; 2010 Jul; 77(2):337-53. PubMed ID: 20487280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice.
    Lee HY; Cho SA; Lee IS; Park JH; Seok SH; Baek MW; Kim DJ; Lee SH; Hur SJ; Ban SJ; Lee YK; Han YK; Cho YK; Park JH
    FEMS Immunol Med Microbiol; 2007 Nov; 51(2):310-8. PubMed ID: 17725620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal
    Schager AE; Dominguez-Medina CC; Necchi F; Micoli F; Goh YS; Goodall M; Flores-Langarica A; Bobat S; Cook CNL; Arcuri M; Marini A; King LDW; Morris FC; Anderson G; Toellner KM; Henderson IR; López-Macías C; MacLennan CA; Cunningham AF
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever.
    Das S; Chowdhury R; Pal A; Okamoto K; Das S
    Immunobiology; 2019 May; 224(3):371-382. PubMed ID: 30952553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.